Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
betamethasone valerate + dithranol
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
A topical combination therapy used for the treatment of psoriasis. It combines betamethasone valerate, a potent corticosteroid that reduces inflammation, with dithranol (anthralin), which inhibits DNA replication and cell division in psoriatic plaques. The combination targets both the inflammatory component and the abnormal cell proliferation characteristic of psoriasis.
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on betamethasone valerate + dithranol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on betamethasone valerate + dithranol.